A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)

Background: Pembrolizumab shows robust antitumor activity and favorable safety in metastatic melanoma. KEYNOTE-151 evaluated pembrolizumab in Chinese patients, who have more aggressive melanoma subtypes than other populations. Methods: Chinese patients aged ≥18 years with advanced melanoma previousl...

Full description

Bibliographic Details
Main Authors: Lu Si, Xiaoshi Zhang, Yongqian Shu, Hongming Pan, Di Wu, Jiwei Liu, Fang Lou, Lili Mao, Xuan Wang, Xizhi Wen, Yanhong Gu, Lingjun Zhu, Shijie Lan, Xin Cai, Scott J. Diede, Yu Zhou, Jun Ge, Jianfeng Li, Haiyan Wu, Jun Guo
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523318305916

Internet

http://www.sciencedirect.com/science/article/pii/S1936523318305916

Similar Items